Daxor Corporation (DXR)
NASDAQ: DXRHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DXR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $43.49M
- P/E (TTM)
- 6.77
- EPS (TTM)
- $1.10
- Dividend yield
- None
- Ex-dividend date
- Jan 5, 2018
- 52-week range
- 6.94 – 14.76
- Day range
- 7.00 – 7.88
- Volume / Avg
- 33.83K / 22.43K
- Beta
- —
- Shares outstanding
- 5.84M
52-week range
DXR stock today
Daxor (DXR) closed at $7.45 on Nov 20, down 7.33% (-$0.5891), versus the S&P 500's 3.70% decline. At this level, DXR sits near the bottom of its 52-week range of $6.94 to $14.76: 49.5% below the high, set on Dec 29, 2025 and 7.3% above the low. DXR is down 49.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 43.5%.
Daxor trades at 6.8x its trailing twelve-month earnings per share of $1.10.
Summary generated from market data by MetaCap's automated system. Methodology
About Daxor
Company profileDaxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael Richard Feldschuh
- Headquarters
- Oak Ridge, TN
- Website
- daxor.com
Financial highlights
Full financialsIn fiscal 2011, Daxor generated $1.4 million in revenue, down 8.4% from fiscal 2010, the first decline in the 2 years shown. Daxor reported a net loss of $7.2 million, compared with net income of $5.0 million a year earlier. Gross margin was 54.9% (up from 53.9%) and operating margin -400.1%.
| Fiscal year | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $1.45M | $1.58M |
| Growth | -8.42% | — |
| Net income | $-7.19M | $4.97M |
| EPS (diluted) | $-1.70 | $1.17 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$20.00+168.46%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2011)
- Nov 14, 2011
- EPS actual vs est.
- $-0.99 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.03
- Ex-dividend date
- Jan 5, 2018
DXR news
All DXR newsDaxor peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MBOTMicrobot Medical Inc. | 0.68 | -8.52% | $45.67M | vs DXR |
| SRTSSensus Healthcare Inc. | 2.26 | -4.24% | $37.20M | vs DXR |
| MDAISpectral AI Inc. Class A | 1.04 | -20.61% | $33.47M | vs DXR |
| LNSRLENSAR Inc. | 4.46 | -3.88% | $54.83M | vs DXR |
| TELATELA Bio Inc. | 0.6885 | -5.27% | $31.11M | vs DXR |
| XTNTXtant Medical Holdings Inc. | 0.21 | -2.82% | $29.49M | vs DXR |
| NSPRInspireMD Inc. | 0.54 | -12.97% | $29.23M | vs DXR |
| NEPHNephros Inc. | 2.61 | -8.10% | $28.37M | vs DXR |
Indexes, lists and sector
Daxor stock FAQ
What is Daxor's stock price today?
DXR last traded at $7.45 as of Nov 20, 4:00 PM EST, down 7.33% on the day. Prices are delayed at least 15 minutes.
Does Daxor pay a dividend?
Yes. Daxor pays $0.00 per share annually. The most recent dividend of $0.03 had an ex-dividend date of Jan 5, 2018.
What is DXR's P/E ratio?
DXR trades at a trailing P/E ratio of 6.77.
Who is Daxor's CEO?
Mr. Michael Richard Feldschuh is the chief executive officer of Daxor Corporation.
What is the DXR 52-week high?
The 52-week high for DXR is $14.76 and the 52-week low is $6.94. The stock is currently 49.5% below its high.